Co-Fluorescence Enhancement Solution
The CFES based on PTA-Y34 was as described elsewhere (21). The CFES comprises two parts: the dissociative part, 70 mol of PTA, 7.5 mol of Y34, 0.6 g of Triton X-100, and 300 mL of ethanol per liter, adjusted to pH 3.5 with acetic acid; and the enhancing part, 0.5 mmol of phenanthroline and 0.2 mol of Tris per liter.
Stored at 4#{176}C in the dark, the CFES was brought to room temperature just before use.
Standards
To simplify the standardization of the quadruple-label assay, we arranged the standards to give increasing ion concentrations.
Thus the standard concentrations for the three noncompetitive analyses were arranged in ascending order but for the competitive 17a-OHP assay were in descending order (Table 2 ). This arrangement avoided the need to correct for signal cross-talk between the signals for the standards (for unknown samples, this correction still had to be made).
Procedures

Labeling the immunoreagents.
The labeling of anti-TSH, anti-IRT, and goat-anti-CK-MM with Eu34, Sm34, and Dy3, respectively, was performed in overnight incubations, with 50-to 500-fold molar excesses of the labeling reagents in a 50 mmollL carbonate buffer, pH 8.5 or 9.8, at 4#{176}C or at room temperature.
The labeled Table 1 .
Sample Specimens
Dried blood specimens were kindly donated by Dr. N#{216}rgaard-Pedersen (Statens Seruminstitut, Copenhagen, Denmark), Dr. Scheuerbrandt (CK Test Laboratoriwn, Breitnau, FRG), and Dr. Torresani (Kinderspital, Zurich, Switzerland).
Results
Simultaneous Detection of Eu34, Tb, Sm3t and Dy3
A three-dimensional proffle, including the emission intensity, emission wavelength, and time delay, of the lanthanide-chelate luminescences in the CFES after excitation at 315 nm is shown in Figure 1 . The strongest emission peaks were obtained at 612 nm for Eu34, 544 mu forTh34, 647 mu for Sm34, and 574 nm for Dy34; the respective decay times were 820, 323, 88, and 27 pa. Table 3 Table  4 . Figure 2 shows the dose-response curves of the assay and the precision proffles calculated from 12 replicates of the standards. The detection limits were 0.1 mlU/L for TSH, 2 nmolfL for 17a-OHP, 2 pgfL for IRT, and 4 U/L for CK-MM, as calculated from the imprecision of the lowest standard (1 mJUfL standard for TSH and zero standard for others) and defined as the response giving a signal equivalent to the mean + 3 SD of the signal for the zero standard. Table 5 lists the detection limits, dynamic ranges, and precisions of the assays of TSH, 17a-OHP, and IRT of the quadruple-label assay, in comparison with the respective Delfia single-label assays. The detection limit of the co-fluorescent TSH assay is 10-fold lower than that of the corresponding Deffia kits, whereas the re- inating from different labels. However, because of the considerable differences not only in the emission spectra but also in the decay times of the four ions in CFES (Table 1) , the fluorescence interferences were negligible or insignificant except for that from Sm34 to Dy3 (Table 3) . A simple mathematical correction can be used after measuring all the ions to subtract the unwanted spillover signal when needed.
Quadruple-Label Assay
In designing the quadruple-label assay, we assigned the labels according to the sensitivity required for each analyte, the fluorescence background of CFES, and the fluorescence interference. Because the assays of TSH and 17a-OHP required greater sensitivities (lower detection limits), Eu3 and Th34 were assigned to these analytes.
Because the interference from Sm34 in the detection of Dy34 was considerable and because the amount of fluorescence produced by Dy3 exceeded that of Sm3 (Table 3) , we assigned Dy to the CK-MM assay, which gives a greater signal than the IRT assay. In addition, by controlling the amount of label, the signals can be adjusted to decrease the possible spillover problem; therefore, we used a higher concentration of label for Dy34 (20 Dy3 per IgG molecule) than for Sm34 (15 Sm3 per IgG molecule). In the assay of unknown samples, the raw data were recalculated according to the factors in Table 4 to obtain corrected results.
Despite the accommodation of four solid-phase assays in the same well sharing the same limited binding capacity of the microtitration well surface, the dynamic ranges were similar to those of the respective singlelabel assays. This is partly explained by the fact that the sample volume used in the test, -4 L of plasma, is relatively small; therefore, antibody excess situations are easily achieved in ratio to the analyte concentration likely to be found in this volume of sample. This is also illustrated by the fact that the dynamic range of the single-label Delfia TSH kit, which requires 50-L serum samples, is >10-fold the range needed in neonatal screening.
In addition, we used more antibody to coat the microtitration strip wells in the present study than is used in the single-label Delfia kits, for a more efficient utilization of the available surface. 
